AFTERNOON SEMINAR AS2

Novel Engineered AAVs for Targeting Retina

2024年7月16日（火） | 15:50 ～ 16:30
第3会場（パシフィコ横浜会議センター 3階 304）

共催：第30 回日本遺伝子細胞治療学会学術集会 / Revvity, Inc.

Abstract:

The evolution of large AAV libraries *in vivo* has led to the identification of novel vector variants with enhanced transduction of target cells and liver de-targeted phenotypes. To assess the efficiency of these vectors, they need to be screened in animal models close to humans, preferably in non-human primates (NHP).

Revvity has evolved vectors for retinal gene transfer and analyzed the transduction of multiplexed vectors following subretinal dosing at the single-cell level. Selected variants outperformed parental vectors based on AAV2 and AAV8 up to 30-fold and achieved transduction rates of up to 75% of target cells at vector doses as low as 1E9vg.

座長

Ryuichi Uozumi, Ph.D.
Product Specialist
Revvity Preclinical Services

演者

Dr. Yvonne Berghöfer-Hochheimer
Head of Alliance and
Program Management
Revvity Gene Delivery GmbH
Munich, Germany

Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA
www.revvity.com